Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies

被引:9
作者
Gorse, GJ
Patel, GB
Mandava, MD
Belshe, RB
机构
[1] St Louis Univ, Sch Med, St Louis, MO USA
[2] St Louis Dept Vet Affairs Med Ctr, St Louis, MO USA
关键词
HIV-1; vaccines; cytotoxic T lymphocytes; cellular immunity;
D O I
10.1016/S0264-410X(99)00323-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CD8+ cytotoxic T lymphocytes (CTL) against human immunodeficiency virus type 1 (HIV-1) induced by candidate HIV-1 vaccines may be a mechanism of immune protection against HIV-1 infection. We measured in vitro inducible CD8+ and CD4+ CTL using two in vitro effector cell stimulation strategies. Peripheral blood mononuclear cells (PBMC) for CTL assay were obtained after the third and/or fourth immunization timepoints from 23 healthy, uninfected adult volunteers, of whom 19 received a canarypox virus vaccine expressing HIV-1 env, gag, pol, nef and protease gene products (vCP300) with or without injections of HIV-1(SF-2) rgp120 subunit vaccine and four subjects received only control injections. CD8+ CTL activity was detected employing the two in vitro stimulation strategies against one or more HIV-1 antigens in 15 (79%) of 19 HIV-1 vaccine recipients on at least one occasion and repeatedly against the same antigen in 8 (42%. Canarypox virus-based HIV-1 vaccines represent a step forward in HIV-1 vaccine development. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:835 / 849
页数:15
相关论文
共 49 条
[1]   Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers [J].
Belshe, RB ;
Gorse, GJ ;
Mulligan, MJ ;
Evans, TG ;
Keefer, MC ;
Excler, JL ;
Duliege, AM ;
Tartaglia, J ;
Cox, WI ;
McNamara, J ;
Hwang, KL ;
Bradney, A ;
Montefiori, D ;
Weinhold, KJ .
AIDS, 1998, 12 (18) :2407-2415
[2]   VIRUS-SPECIFIC CD8+ CYTOTOXIC T-LYMPHOCYTE ACTIVITY ASSOCIATED WITH CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
BORROW, P ;
LEWICKI, H ;
HAHN, BH ;
SHAW, GM ;
OLDSTONE, MBA .
JOURNAL OF VIROLOGY, 1994, 68 (09) :6103-6110
[3]  
BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
[4]   BIOLOGY OF CLONED CYTO-TOXIC LYMPHOCYTES-T SPECIFIC FOR LYMPHOCYTIC CHORIOMENINGITIS VIRUS - CLEARANCE OF VIRUS INVIVO [J].
BYRNE, JA ;
OLDSTONE, MBA .
JOURNAL OF VIROLOGY, 1984, 51 (03) :682-686
[5]   QUANTITATIVE-ANALYSIS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SPECIFIC CYTOTOXIC LYMPHOCYTE-T (CTL) RESPONSE AT DIFFERENT STAGES OF HIV-1 INFECTION - DIFFERENTIAL CTL RESPONSES TO HIV-1 AND EPSTEIN-BARR-VIRUS IN LATE DISEASE [J].
CARMICHAEL, A ;
JIN, X ;
SISSONS, P ;
BORYSIEWICZ, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) :249-256
[6]   CYTOTOXIC LYMPHOCYTE-T RESPONSES IN THE PERIPHERAL-BLOOD OF CHILDREN BORN TO HUMAN IMMUNODEFICIENCY VIRUS-1-INFECTED MOTHERS [J].
CHEYNIER, R ;
LANGLADEDEMOYEN, P ;
MARESCOT, MR ;
BLANCHE, S ;
BLONDIN, G ;
WAINHOBSON, S ;
GRISCELLI, C ;
VILMER, E ;
PLATA, F .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (09) :2211-2217
[7]   Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults [J].
Clements-Mann, ML ;
Weinhold, K ;
Matthews, TJ ;
Graham, BS ;
Gorse, GJ ;
Keefer, MC ;
McElrath, MJ ;
Hsieh, RH ;
Mestecky, J ;
Zolla-Pazner, S ;
Mascola, J ;
Schwartz, D ;
Siliciano, R ;
Corey, L ;
Wright, PF ;
Belshe, R ;
Dolin, R ;
Jackson, S ;
Xu, S ;
Fast, P ;
Walker, MC ;
Stablein, D ;
Excler, JL ;
Tartaglia, J ;
Duliege, AM ;
Sinangil, F ;
Paoletti, E .
JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (05) :1230-1246
[8]   ENHANCED IMMUNITY TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) ENVELOPE ELICITED BY A COMBINED VACCINE REGIMEN CONSISTING OF PRIMING WITH A VACCINIA RECOMBINANT EXPRESSING HIV ENVELOPE AND BOOSTING WITH GP160-PROTEIN [J].
COONEY, EL ;
MCELRATH, MJ ;
COREY, L ;
HU, SL ;
COLLIER, AC ;
ARDITTI, D ;
HOFFMAN, M ;
COOMBS, RW ;
SMITH, GE ;
GREENBERG, PD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (05) :1882-1886
[9]   Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen [J].
Corey, L ;
McElrath, MJ ;
Weinhold, K ;
Matthews, T ;
Stablein, D ;
Graham, B ;
Keefer, M ;
Schwartz, D ;
Gorse, G .
JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (02) :301-309
[10]   Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney blood bank cohort patients infected with nef-defective HIV type 1 [J].
Dyer, WB ;
Ogg, GS ;
Demoitie, MA ;
Jin, X ;
Geczy, AF ;
Rowland-Jones, SL ;
McMichael, AJ ;
Nixon, DF ;
Sullivan, JS .
JOURNAL OF VIROLOGY, 1999, 73 (01) :436-443